Pfizer vaccine for children 5-11 years, “90.7% effective and safe”

The results of Pfizer-BioNTech’s Phase 2/3 Covid vaccine study in children aged 5 to 11 have been published in the ‘New England Journal of Medicine’. The American Pfizer announces it “with pride” via Twitter. “In this multiphase study – tweets the ‘Nejm’ recalling the results of the trial – 2 doses of 10 micrograms”, one third of the dosage approved for the older ones, “of the vaccine BNT162b2, given 21 days apart, proved to be safe. , immunogenic and 90.7% effective against Covid-19 in children aged between 5 and 11 years “.